Taziflo 12,5; 25 & 50 12,5; 25 & 50 mg Tablet
PDF Leaflet Revision Date: 26 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Oedema and essential hypertension management.
Dosage (summary)
Adults: 12.5 mg to 200 mg daily; take in the morning with food.
Onset of Action / Duration
Onset: 2 hours, Duration: 12 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy (2nd/3rd trimester) or breastfeeding.
Key Drug Interactions
- Antidiabetic medications
- Lithium
- Corticosteroids
- NSAIDs
Contraindications
- Hypersensitivity to hydrochlorothiazide
- Anuria
- Severe renal insufficiency
- Severe hepatic impairment
- Addison's disease
- Hypercalcaemia
Common side effects
- Hypokalaemia
- Dizziness
- Headache
- Nausea
- Photosensitivity
Counselling Points
- Monitor blood pressure regularly
- Stay hydrated
- Report any skin changes
- Avoid sun exposure
Serious warnings
- Risk of electrolyte imbalance
- Potential for acute angle-closure glaucoma
- Increased risk of non-melanoma skin cancer
Important Disclaimer
The Taziflo 12,5; 25 & 50 12,5; 25 & 50 mg Tablet professional information leaflet below is the property of Austell Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
